A Non-interventional Post Authorisation Registry of Patients Treated With Pomalidomide for Relapsed and Refractory Multiple Myeloma Who Have Received at Least Two Prior Treatment Regimens, Including Both Lenalidomide and Bortezomib, and Have Demonstrated Disease Progression on the Last Therapy
A Non-interventional Post Authorisation Registry of Patients Treated With Pomalidomide for Relapsed and Refractory Multiple Myeloma Who Have Received at Least Two Prior Treatment Regimens, Including Both Lenalidomide and Bortezomib, and Have Demonstrated Disease Progression on the Last Therapy
This registry is a prospective, multi-center, observational study and will collect safety data on multiple myeloma adult patients who have received at least two prior therapies and take IMNOVID (pomalidomide) as part of standard care.
The registry will remain open until 500 patients will have received at least 3 cycles of pomalidomide. All patients registered will be followed for up to 3 years after the informed consent date or until death or withdrawal of consent. During this time the incidence of second primary malignancies (SPM), overall survival and any occurrence of a pregnancy will be assessed.
Inclusion Criteria:
Understand and voluntarily sign an informed consent form, if applicable, and have never been previously treated with pomalidomide before their inclusion in the Registry.
Patients with symptomatic, measurable relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both bortezomib and lenalidomide and have demonstrated disease progression on the last therapy and are commencing a pomalidomide based treatment.
Exclusion Criteria:
Refusal to participate in the Registry or currently participating in the treatment phase of an interventional clinical trial.
Pregnancy.
Women of childbearing potential, unless all the conditions of the pregnancy prevention program are met.
Male patients unable to follow or comply with the required contraceptive measures.
Hypersensitivity to the active substance or to any of the excipients.
Koln-Kalk, Buchforststr 14 51103, Germany
München, Marchioninistr. 15 81377, Germany
Kronach, Niederbronner Stabe 2 96317, Germany
Hamburg, 20259, Germany
Minden, 32429, Germany
Brescia, 25123, Italy
Torrette Di Ancona, 60126, Italy
Santa Cruz de Tenerife, Carretera Del Rosario, 145 38010, Spain
Doncaster, Armthorpe Road DN25LT, United Kingdom
County Durham, Darlington Memorial Hospital DL3 6HX, United Kingdom
Broomfield,Chelmsford, Essex CM1 7ET, United Kingdom
Newcastle upon Tyne, Freeman Hospital NE7 7DN, United Kingdom
Lincoln, Greetwell Road LN2 5QY, United Kingdom
Maidstone, Kent ME16 9QQ, United Kingdom
Blackpool, Lancashire FY3 8NR, United Kingdom
Huddersfield, Lindley HD3 3EA, United Kingdom
Worthing, Lyndhurst Road BN11 2DH, United Kingdom
Airdrie, Monkscourt Avenue ML6 OJS, United Kingdom
Bristol, Southmead Road BS10 5NB, United Kingdom
Sunderland, Sunderland Royal Hospital SR4 7TP, United Kingdom
Colchester, Turner Road CO4 5JL, United Kingdom
Harrow, Watford Road HA1 3UJ, United Kingdom
Swansea, West Glamorgan SA2 8QA, United Kingdom
Worcester, Worcestershire WR5 1DD, United Kingdom
Carshalton, Wrythe Lane SM5 1AA, United Kingdom
Oxford, OX3 7LJ, United Kingdom
Tyne and Wear, NE29 8NH, United Kingdom